This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lam, A. K. Y. Articles by Luk, J. M. Search for Related Content PubMed PubMed Citation Articles by Lam, A. K. Y. Articles by Luk, J. M.

Clinicopathological Roles of Alterations of Tumor Suppressor Gene p16 in Papillary Thyroid Carcinoma

¹ Discipline of Pathology, School of Medicine, Griffith University, PMB 50 Gold Coast Mail Centre, Queensland 9726, Australia
² Department of Surgery, Faculty of Medicine, University of Hong Kong, Pokfulam Road, Hong Kong, China

Correspondence: Address correspondence and reprint requests to: Alfred King Yin Lam, MBBS, MD, PhD, FRCPA; E-mail: a.lam{at}griffith.edu.au

Background: Alterations of the p16 gene are common in human cancers, but their roles in thyroid cancers have not been clearly defined. The aim of the present study was to investigate the clinicopathological roles of the p16 gene in papillary thyroid carcinoma (PTC).

Methods: p16 gene alterations were investigated in 44 patients with PTC (9 men, 35 women) by immunohistochemistry, reverse transcriptase–polymerase chain reaction and methylation-specific polymerase chain reaction. The findings were correlated with their clinicopathological features.

Results: p16 protein expression, mRNA alterations, and promoter methylation were detected in 89% (n = 39), 77% (n = 33), and 41% (n = 18) of patients with PTC, respectively. There was no marked relationship between p16 protein expression, mRNA alteration, and promoter methylation. In follicular variant of PTC (FVPTC), there was a frequent lack of p16 protein expression and promoter methylation. PTCs showing p16 promoter methylation were often associated with a high AMES (age, metastasis to distant sites, extrathyroidal invasion, size) risk group and advanced pTNM (tumor–lymph node–metastasis) stages.

Conclusions: p16 gene alterations are common and correlate with histological features and biological aggressiveness in PTC, suggesting that they might play an important role in its pathogenesis.

Key Words: p16 • Expression • Methylation • Papillary thyroid carcinoma

This article has been cited by other articles:

				S. M. Wiseman, A. Melck, H. Masoudi, F. Ghaidi, L. Goldstein, A. Gown, S. J. M. Jones, and O. L. Griffith Molecular Phenotyping of Thyroid Tumors Identifies a Marker Panel for Differentiated Thyroid Cancer Diagnosis Ann. Surg. Oncol., October 1, 2008; 15(10): 2811 - 2826. [Abstract] [Full Text] [PDF]

				A Salajegheh, E B Petcu, R A Smith, and A K-Y Lam Follicular variant of papillary thyroid carcinoma: a diagnostic challenge for clinicians and pathologists Postgrad. Med. J., February 1, 2008; 84(988): 78 - 82. [Abstract] [Full Text] [PDF]

				A. Melck, H. Masoudi, O. L. Griffith, A. Rajput, G. Wilkins, S. Bugis, S. J. M. Jones, and S. M. Wiseman Cell Cycle Regulators Show Diagnostic and Prognostic Utility for Differentiated Thyroid Cancer. Ann. Surg. Oncol., December 1, 2007; 14(12): 3403 - 3411. [Abstract] [Full Text] [PDF]